FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3188045674> ?p ?o ?g. }

• W3188045674 abstract "Abstract Background Acute hepatic porphyria (AHP) is a rare, debilitating disease characterized by potentially life-threatening attacks often resulting in chronic symptoms that negatively impact daily functioning and quality of life. Symptoms of AHP prevent many individuals from working and achieving lifetime work averages. The aim of this study was to apply a public economic framework to evaluate AHP in Belgium, taking into consideration a broad range of costs that are relevant to government in relation to social benefit payments and lifetime taxes paid. Methodology A public economic framework was developed exploring lifetime costs for government attributed to an individual with AHP and recurrent attacks in Belgium. Work-activity and lifetime direct taxes paid, indirect consumption taxes and requirements for public benefits were estimated based on established clinical pathways for AHP and compared to the general population (GP). The model includes AHP-related healthcare costs and non-AHP healthcare costs for the GP. Results Lifetime earnings are reduced in an individual with AHP by €347,802 per person (p.p.), translating to reduced lifetime taxes paid of €183,187 for an AHP individual compared to the GP. We estimate increased lifetime disability benefit support of €247,242 for an AHP individual compared to GP. Lifetime healthcare costs for a person with AHP were estimated to be €3,030,316 due to frequent hospitalisations associated with porphyria attacks compared to the GP. The lifetime costs for a person with 12 attacks per annum factoring in transfers, taxes and healthcare costs are estimated to be €3,460,745 p.p. Eliminating AHP attacks after 10 years of active disease, thus, enabling a person to return to work increases lifetime earnings by €224,575 p.p. Increased work activity in such individuals would generate an estimated €118,284 p.p. over their lifetime. The elimination of AHP attacks could also lead to reductions in disability payments of €179,184 p.p. and healthcare cost savings of €1,511,027 p.p. Conclusions Due to severe disability resulting from constant attacks, AHP patients with recurrent attacks incur significant public costs. Lifetime taxes paid are reduced as these attacks occur during peak earning and working years. In those patients, reducing AHP attacks can confer significant fiscal benefits for government, including reduced healthcare costs, reduced disability payments and improved tax revenue." @default.
• W3188045674 created "2021-08-16" @default.
• W3188045674 creator A5003278427 @default.
• W3188045674 creator A5023835730 @default.
• W3188045674 creator A5028321574 @default.
• W3188045674 creator A5053190637 @default.
• W3188045674 creator A5074079949 @default.
• W3188045674 date "2021-08-04" @default.
• W3188045674 modified "2023-09-26" @default.
• W3188045674 title "Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework" @default.
• W3188045674 cites W1591838662 @default.
• W3188045674 cites W1709418723 @default.
• W3188045674 cites W1714222561 @default.
• W3188045674 cites W1985874257 @default.
• W3188045674 cites W2033770456 @default.
• W3188045674 cites W2042726772 @default.
• W3188045674 cites W2044487970 @default.
• W3188045674 cites W2063419295 @default.
• W3188045674 cites W2100073287 @default.
• W3188045674 cites W2119952655 @default.
• W3188045674 cites W2131786905 @default.
• W3188045674 cites W2151599925 @default.
• W3188045674 cites W2153398526 @default.
• W3188045674 cites W2160983390 @default.
• W3188045674 cites W2510655756 @default.
• W3188045674 cites W2590564871 @default.
• W3188045674 cites W2625865516 @default.
• W3188045674 cites W2790744750 @default.
• W3188045674 cites W2801321266 @default.
• W3188045674 cites W2897976652 @default.
• W3188045674 cites W2906242437 @default.
• W3188045674 cites W2947843510 @default.
• W3188045674 cites W2972591640 @default.
• W3188045674 cites W3033201788 @default.
• W3188045674 cites W4210973172 @default.
• W3188045674 cites W4253050377 @default.
• W3188045674 doi "https://doi.org/10.1186/s13023-021-01966-3" @default.
• W3188045674 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8336398" @default.
• W3188045674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34348763" @default.
• W3188045674 hasPublicationYear "2021" @default.
• W3188045674 type Work @default.
• W3188045674 sameAs 3188045674 @default.
• W3188045674 citedByCount "2" @default.
• W3188045674 countsByYear W31880456742022 @default.
• W3188045674 countsByYear W31880456742023 @default.
• W3188045674 crossrefType "journal-article" @default.
• W3188045674 hasAuthorship W3188045674A5003278427 @default.
• W3188045674 hasAuthorship W3188045674A5023835730 @default.
• W3188045674 hasAuthorship W3188045674A5028321574 @default.
• W3188045674 hasAuthorship W3188045674A5053190637 @default.
• W3188045674 hasAuthorship W3188045674A5074079949 @default.
• W3188045674 hasBestOaLocation W31880456741 @default.
• W3188045674 hasConcept C100001284 @default.
• W3188045674 hasConcept C10138342 @default.
• W3188045674 hasConcept C121955636 @default.
• W3188045674 hasConcept C127413603 @default.
• W3188045674 hasConcept C138885662 @default.
• W3188045674 hasConcept C144133560 @default.
• W3188045674 hasConcept C145097563 @default.
• W3188045674 hasConcept C160735492 @default.
• W3188045674 hasConcept C162118730 @default.
• W3188045674 hasConcept C162324750 @default.
• W3188045674 hasConcept C2778137410 @default.
• W3188045674 hasConcept C2781426361 @default.
• W3188045674 hasConcept C2908647359 @default.
• W3188045674 hasConcept C41895202 @default.
• W3188045674 hasConcept C42475967 @default.
• W3188045674 hasConcept C50522688 @default.
• W3188045674 hasConcept C6964187 @default.
• W3188045674 hasConcept C71924100 @default.
• W3188045674 hasConcept C87345402 @default.
• W3188045674 hasConcept C99454951 @default.
• W3188045674 hasConceptScore W3188045674C100001284 @default.
• W3188045674 hasConceptScore W3188045674C10138342 @default.
• W3188045674 hasConceptScore W3188045674C121955636 @default.
• W3188045674 hasConceptScore W3188045674C127413603 @default.
• W3188045674 hasConceptScore W3188045674C138885662 @default.
• W3188045674 hasConceptScore W3188045674C144133560 @default.
• W3188045674 hasConceptScore W3188045674C145097563 @default.
• W3188045674 hasConceptScore W3188045674C160735492 @default.
• W3188045674 hasConceptScore W3188045674C162118730 @default.
• W3188045674 hasConceptScore W3188045674C162324750 @default.
• W3188045674 hasConceptScore W3188045674C2778137410 @default.
• W3188045674 hasConceptScore W3188045674C2781426361 @default.
• W3188045674 hasConceptScore W3188045674C2908647359 @default.
• W3188045674 hasConceptScore W3188045674C41895202 @default.
• W3188045674 hasConceptScore W3188045674C42475967 @default.
• W3188045674 hasConceptScore W3188045674C50522688 @default.
• W3188045674 hasConceptScore W3188045674C6964187 @default.
• W3188045674 hasConceptScore W3188045674C71924100 @default.
• W3188045674 hasConceptScore W3188045674C87345402 @default.
• W3188045674 hasConceptScore W3188045674C99454951 @default.
• W3188045674 hasFunder F4320309056 @default.
• W3188045674 hasIssue "1" @default.
• W3188045674 hasLocation W31880456741 @default.
• W3188045674 hasLocation W31880456742 @default.
• W3188045674 hasLocation W31880456743 @default.
• W3188045674 hasLocation W31880456744 @default.
• W3188045674 hasLocation W31880456745 @default.
• W3188045674 hasLocation W31880456746 @default.

• next